Form 8-K - Current report:
SEC Accession No. 0001140361-25-034845
Filing Date
2025-09-12
Accepted
2025-09-12 16:13:10
Documents
12
Period of Report
2025-09-12
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K ef20055483_8k.htm   iXBRL 8-K 40694
  Complete submission text file 0001140361-25-034845.txt   169466

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA grce-20250912.xsd EX-101.SCH 3859
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE grce-20250912_lab.xml EX-101.LAB 21966
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE grce-20250912_pre.xml EX-101.PRE 16040
15 EXTRACTED XBRL INSTANCE DOCUMENT ef20055483_8k_htm.xml XML 4232
Mailing Address 103 CARNEGIE CENTER SUITE 300 PRINCETON NJ 08540
Business Address 103 CARNEGIE CENTER SUITE 300 PRINCETON NJ 08540 609-322-1602
Grace Therapeutics, Inc. (Filer) CIK: 0001444192 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-35776 | Film No.: 251311646
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)